Back to Search
Start Over
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
- Publication Year :
- 2020
-
Abstract
- Objectives The incidence of any and of severe-grade immune-related adverse events (irAEs) with second-line nivolumab monotherapy is 31–65 % and 2–5 % respectively. While potentially serious and even fatal, in the absence of an appropriate therapy, such events might be indicators of the activation of the immune system and, potentially, of efficacy. Materials and Methods We collected the records of 1959 non-small-cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access program, and we registered the appearance of any and of severe grade irAEs. We retrospectively searched for correlations between toxicity and efficacy parameters by using Cox's regression analysis. Results Overall, 342 (17.8%) patients developed an irAE of any grade. We observed that patients developing irAE of any grade achieved a significantly higher response rate (RR 27.2% vs 15.2%; p Conclusions This report, performed in Caucasian NSCLC patients, showed that the appearance of irAEs correlated with outcome.
- Subjects :
- 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Cancer Research
medicine.medical_specialty
Outcomes
NO
Efficacy
03 medical and health sciences
0302 clinical medicine
Immuno-Related adverse events
Immunopathology
Internal medicine
medicine
Nivolumab
Progression-free survival
Lung cancer
Adverse effect
business.industry
Retrospective cohort study
medicine.disease
030104 developmental biology
030220 oncology & carcinogenesis
Expanded access
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....a28894fc3abc7f2350fa495f0a094b05